Related Experiment Video

Updated: May 9, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

IL-32 as a potential biomarker and therapeutic target in cardiovascular disease

Lingyue Qiu1, Jing Ye2, Ling Liu1

  • 1Guangxi Chest Pain Center, and Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Institute of Cardiovascular Diseases, Guangxi Academy of Medical Sciences, Nanning, China.

Frontiers in Immunology
|May 8, 2026
PubMed

Insights

Interleukin-32 (IL-32) is a key cytokine in cardiovascular diseases like atherosclerosis and heart failure. Understanding IL-32

Area of Science:

  • Cardiovascular biology
  • Immunology
  • Cytokine research

Background:

  • Cardiovascular diseases (CVDs) are a major global health burden.
  • Inflammation and cytokines play critical roles in CVD pathogenesis.
  • Interleukin-32 (IL-32) is a recently identified cytokine implicated in various diseases.

Purpose of the Study:

  • To review the biological characteristics of IL-32.
  • To elucidate the role of IL-32 in the pathogenesis of cardiovascular diseases.
  • To evaluate IL-32 as a potential biomarker and therapeutic target for CVDs.

Main Methods:

  • Literature review of studies on IL-32 and cardiovascular diseases.
  • Analysis of IL-32's involvement in inflammatory pathways.
  • Evaluation of IL-32's association with atherosclerosis, myocardial infarction, and heart failure.

Main Results:

  • IL-32 is involved in the inflammatory processes underlying cardiovascular pathologies.
  • Evidence links IL-32 to the development and progression of atherosclerosis, myocardial infarction, and heart failure.
  • IL-32 demonstrates potential as a diagnostic biomarker and a therapeutic target in CVDs.

Conclusions:

  • IL-32 is a significant factor in cardiovascular disease development and progression.
  • Targeting IL-32 may offer novel therapeutic strategies for cardiovascular diseases.
  • Further research into IL-32's mechanisms can inform future prevention and treatment approaches.

Keywords:
IL-32biomarkercardiovascular diseasescytokinesinflammation

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...